tert-butyl (2-fluoro-5-nitrophenyl)carbamate | 535170-15-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: tert-butyl (2-fluoro-5-nitrophenyl)carbamate
• 英文别名: tert-butyl 2-fluoro-5-nitrophenylcarbamate；2-fluoro-5-nitro-t-butoxycarbonylaniline；tert-butyl N-(2-fluoro-5-nitrophenyl)carbamate
• CAS: 535170-15-1
• 化学式: C₁₁H₁₃FN₂O₄
• 分子量: 256.234
• InChiKey: ZEAGQPDAEUBUAX-UHFFFAOYSA-N

物化性质

• 沸点：
  292.8±30.0 °C(Predicted)
• 密度：
  1.317±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  84.2
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  tert-butyl (2-fluoro-5-nitrophenyl)carbamate 在 钯 氮 、 氢气 、 甲醇 作用下， 以 乙醇 、 四氢呋喃 为溶剂， 反应 16.0h， 以to get crude product 89的产率得到(5-氨基-2-氟苯基)-氨基甲酸叔丁酯
  参考文献：
  名称：

  SUBSTITUTED PYRIMIDINE COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF

  摘要：

  本公开涉及式（I）的嘧啶化合物，它们的立体异构体，互变异构体，药学上可接受的盐，多晶形，溶剂化物和水合物。本公开还涉及制备这些嘧啶化合物的过程，以及含有它们的制药组合物。本公开所述化合物在治疗，预防或抑制由表皮生长因子受体（EGFR）家族激酶介导的疾病和疾病方面具有用处。

  公开号：

  US20160207905A1
• 作为产物：
  描述：

  邻氟苯甲酸 在 sodium azide 、 草酰氯 、 硫酸 、 potassium nitrate 、 N,N-二甲基甲酰胺 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 生成 tert-butyl (2-fluoro-5-nitrophenyl)carbamate
  参考文献：
  名称：

  A Novel Antibacterial 8-Chloroquinolone with a Distorted Orientation of the N1-(5-Amino-2,4-difluorophenyl) Group

  摘要：

  Fluoroquinolones represent a major class of antibacterial agents with great therapeutic potential. In this study, we designed m-aminophenyl groups as novel N-1 substituents of naphthyridones and quinolones. Among newly synthesized compounds, 7-(3-aminoazetidin-1-yl)-1-(5-amino-2,4-difluorophenyl)-8-chloro-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (4) has extremely potent antibacterial activities against Gram (+) as well as Gram (-) bacteria. This compound is significantly more potent than trovafloxacin against clinical isolates: 30 times against Streptococcus pneumoniae and 128 times against methicillin resistant Staphylococcus aureus. The structure-activity relationship (SAR) study revealed that a limited combination of 1-(5-amino-2,4-difluorophenyl) group, 7-(azetidin-1-yl) group, and 8-Cl atom (or Br atom or Me group) gave potent antibacterial activity. An X-ray crystallographic study of a 7-(3-ethylaminoazetidin-1-yl)-8-chloro derivative demonstrated that the N-1 aromatic group was remarkably distorted out of the core quinolone plane by steric repulsion between the C-8 C1 atom and the N-1 substituent. Furthermore, a molecular modeling study of 4 and its analogues demonstrated that a highly distorted orientation was induced by a steric hindrance of the C-8 substituent, such as Cl, Br, or a methyl group. Thus, their highly strained conformation should be a key factor for the potent antibacterial activity.

  DOI：

  10.1021/jm0205090

文献信息

• [EN] SUBSTITUTED PYRIMIDINE COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF<br/>[FR] COMPOSÉS DE PYRIMIDINE SUBSTITUÉE, COMPOSITIONS ET APPLICATIONS MÉDICINALES CORRESPONDANTES
  申请人：JUBILANT BIOSYS LTD

  公开号：WO2015025197A1

  公开（公告）日：2015-02-26

  The present disclosure relates to pyrimidine compounds of formula (I), their stereoisomers, tautomers, pharmaceutically acceptable salts, polymorphs, solvates, and hydrates thereof. The present disclosure also relates to process of preparation of these pyrimidine compounds, and to pharmaceutical compositions containing them. The compounds of the present disclosure are useful in the treatment, prevention or suppression of diseases and disorders mediated by epidermal growth factor receptor (EGFR) family kinases.

  本公开涉及式(I)的嘧啶化合物，它们的立体异构体、互变异构体、药学上可接受的盐、多型体、溶剂合物和水合物。本公开还涉及制备这些嘧啶化合物的方法，以及含有它们的药物组合物。本公开的化合物在治疗、预防或抑制由表皮生长因子受体（EGFR）家族激酶介导的疾病和紊乱方面具有用途。
• [EN] NITROGENOUS HETEROCYCLIC DERIVATIVES AND THEIR APPLICATION IN DRUGS<br/>[FR] DÉRIVÉS HÉTÉROCYCLIQUES AZOTÉS ET LEUR APPLICATION DANS DES MÉDICAMENTS
  申请人：SUNSHINE LAKE PHARMA CO LTD

  公开号：WO2014012360A1

  公开（公告）日：2014-01-23

  The present invention relates to the field of medicine, provided herein are novel nitrogenous heterocyclic compounds, their preparation methods and their uses as drugs, especially for treatment and prevention of tissue fibrosis. Also provided herein are pharmaceutically acceptable compositions comprising the nitrogenous heterocyclic compounds and the uses of the compositions in the treatment of human or animal tissue fibrosis, especially for human or animal renal interstitial fibrosis, glomerular sclerosis, liver fibrosis, pulmonary fibrosis, peritoneal fibrosis, myocardial fibrosis, dermatofibrosis, postsurgical adhesion, benign prostatic hyperplasia, skeletal muscle fibrosis, scleroderma, multiple sclerosis, pancreatic fibrosis, cirrhosis, myosarcoma, neurofibroma, pulmonary interstitial fibrosis, diabetic nephropathy, alzheimer disease or vascular fibrosis.

  本发明涉及医学领域，提供了新型含氮杂环化合物，其制备方法及其作为药物的用途，特别是用于治疗和预防组织纤维化。还提供了含有这些含氮杂环化合物的药用可接受的组合物，以及这些组合物在治疗人类或动物组织纤维化方面的用途，特别是用于人类或动物肾间质纤维化、肾小球硬化、肝纤维化、肺纤维化、腹膜纤维化、心肌纤维化、皮肤纤维化、术后粘连、良性前列腺增生、骨骼肌纤维化、硬皮病、多发性硬化、胰腺纤维化、肝硬化、肌肉瘤、神经纤维瘤、肺间质纤维化、糖尿病肾病、阿尔茨海默病或血管纤维化。
• Nitrogenous Heterocyclic Derivatives And Their Application In Drugs
  申请人：SUNSHINE LAKE PHARMA CO., LTD.

  公开号：US20150087639A1

  公开（公告）日：2015-03-26

  The present invention relates to the field of medicine, provided herein are novel nitrogenous heterocyclic compounds, their preparation methods and their uses as drugs, especially for treatment and prevention of tissue fibrosis. Also provided herein are pharmaceutically acceptable compositions comprising the nitrogenous heterocyclic compounds and the uses of the compositions in the treatment of human or animal tissue fibrosis, especially for human or animal renal interstitial fibrosis, glomerular sclerosis, liver fibrosis, pulmonary fibrosis, peritoneal fibrosis, myocardial fibrosis, dermatofibrosis, postsurgical adhesion, benign prostatic hyperplasia, skeletal muscle fibrosis, scleroderma, multiple sclerosis, pancreatic fibrosis, cirrhosis, myosarcoma, neurofibroma, pulmonary interstitial fibrosis, diabetic nephropathy, alzheimer disease or vascular fibrosis.

  本发明涉及医学领域，提供了新颖的含氮杂环化合物，其制备方法及其作为药物的用途，特别是用于治疗和预防组织纤维化。还提供了包含这些含氮杂环化合物的药用组合物，以及这些组合物在治疗人类或动物组织纤维化方面的用途，特别是用于人类或动物肾间质纤维化、肾小球硬化、肝纤维化、肺纤维化、腹膜纤维化、心肌纤维化、皮肤纤维化、术后粘连、良性前列腺增生、骨骼肌纤维化、硬皮病、多发性硬化、胰腺纤维化、肝硬化、肌肉肉瘤、神经纤维瘤、肺间质纤维化、糖尿病肾病、阿尔茨海默病或血管纤维化。
• Design and synthesis of novel DFG-out RAF/vascular endothelial growth factor receptor 2 (VEGFR2) inhibitors: 3. Evaluation of 5-amino-linked thiazolo[5,4-d]pyrimidine and thiazolo[5,4-b]pyridine derivatives
  作者：Masaaki Hirose、Masanori Okaniwa、Tohru Miyazaki、Takashi Imada、Tomohiro Ohashi、Yuta Tanaka、Takeo Arita、Masato Yabuki、Tomohiro Kawamoto、Shunichirou Tsutsumi、Akihiko Sumita、Terufumi Takagi、Bi-Ching Sang、Jason Yano、Kathleen Aertgeerts、Sei Yoshida、Tomoyasu Ishikawa

  DOI：10.1016/j.bmc.2012.07.032

  日期：2012.9

  N-methylation of the amine linker could control the twisted molecular conformation leading to improved solubility. These approaches produced N-methyl thiazolo[5,4-b]pyridine-5-amine derivative 5. To maximize the in vivo efficacy, we attempted salt formation of 5. Our result indicated that the besylate monohydrate salt form (5c) showed significant improvement of both solubility and oral absorption. Owing to

  我们的目的是发现具有强活性和足够口服吸收的RAF /血管内皮生长因子受体2（VEGFR2）抑制剂，因此，我们选择了5-氨基连接的噻唑并[5,4- d ]嘧啶衍生物作为前导物化合物具有潜在的激酶抑制活性和所需的溶解性。根据BRAF的X射线共晶体结构数据，设计了新颖的1-氰基-1-甲基乙氧基叔取代基，以占据BRAF“后袋”的疏水区域。另外，我们发现胺连接基的N-甲基化可以控制扭曲的分子构象，从而导致溶解度的提高。这些方法产生了N-甲基噻唑并[5,4 - b ]吡啶-5-胺衍生物5。为了使体内功效最大化，我们尝试了5的成盐作用。我们的结果表明，苯磺酸盐一水合物盐形式（5c）在溶解度和口服吸收方面均表现出显着改善。由于改善的理化特性，化合物5c在HT-29异种移植模型中显示出了抗肿瘤退行的功效。
• Arylalkanes, arylalkenes and aryl-azaalkanes, pharmaceutical compositions containing these compounds and processes for preparing them
  申请人：RUDOLF Klaus

  公开号：US20070208036A1

  公开（公告）日：2007-09-06

  The present invention relates to compounds of general formula R-Z 1 -Z 2 -Z 3 -R  (I), wherein R, R 1 and Z 1 to Z 3 are defined as in claim 1 , the tautomers, the diastereomers, the enantiomers, the mixtures thereof and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, which have valuable pharmacological properties, particularly CGRP-antagonistic properties, pharmaceutical compositions containing these compounds, their use and processes for preparing them.

  本发明涉及一般式R-Z1-Z2-Z3-R(I)的化合物，其中R、R1和Z1至Z3如权利要求1所定义，其互变异构体、对映异构体、立体异构体、其混合物及其与无机或有机酸或碱的生理上可接受的盐，特别是具有有价值的药理学性质，特别是CGRP-拮抗性质的药物组合物，包含这些化合物，它们的用途和制备它们的过程。